Monoclonal antibody MA 33H1
Latest Information Update: 29 Sep 2004
At a glance
- Originator Sanofi-Synthelabo
- Class Antithrombotics; Monoclonal antibodies
- Mechanism of Action Plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 29 Sep 2004 Discontinued - Preclinical for Thrombosis in France (unspecified route)
- 27 Aug 1999 Sanofi and Synthélabo have now merged to form Sanofi-Synthélabo
- 05 Nov 1998 New profile